InflaRx attracts strong investor interest with US share offering turning to kidney

The German biotech company InflarX N.V., which is listed on Nasdaq, is pushing ahead with a strategic repositioning of its pipeline while securing financing for the next stages of development. At the centre of the strategy is the orally available C5a receptor inhibitor izicopan, which is being developed primarily for severe kidney diseases. To support these ambitions, the company has launched a public offering worth US$150m — and market observers expect the full amount to be subscribed.

According to the company, izicopan will initially be developed for ANCA-associated vasculitis (AAV), a rare and potentially life-threatening autoimmune disease frequently linked to severe kidney damage. Planning for a Phase II study is already under way. InflaRx is also evaluating accelerated regulatory pathways, particularly in light of ongoing regulatory developments surrounding the current standard therapy, avacopan.

C5a inhibition moves from emergency medicine toward chronic therapy

InflaRx has positioned itself within the complement field around the C5a receptor pathway, part of the innate immune system. The approach gained particular attention during the COVID-19 pandemic, when founder and intensive care physician Professor Niels Riedemann strongly advocated C5a modulation as a potential treatment option for critically ill patients suffering from hyperinflammation.

Development ultimately took longer than initially expected, but by early summer 2023 the company’s anti-C5a antibody received emergency authorisation in the United States for severe COVID-19 cases, followed by full approval in Europe in 2024. However, as the pandemic subsided, the therapeutic space around severe inflammatory complications of COVID-19 largely disappeared from public attention.

InflaRx subsequently shifted its strategy toward developing an oral small molecule targeting the same pathway in broader chronic indications, thereby moving beyond its earlier “emergency-use” positioning. Timing now appears favourable for that transition. Investor enthusiasm surrounding the public offering also reflects heightened interest following the difficulties currently surrounding Amgen’s competing AAV therapy avacopan.

Questions over Avacopan create opening for competitors

Both the FDA and the EMA have launched investigations into whether all relevant clinical data were fully disclosed during the approval process for avacopan or whether a more selective dataset had been submitted that may have underrepresented adverse events.

The investigations follow reports of severe liver injury, including fatal cases, in some treated patients. Regulatory reviews remain ongoing. Germany’s BfArM had already initiated assessments earlier this spring, while scrutiny from the FDA has only recently escalated into a broader public issue. Amgen strongly denies any deliberate concealment of safety data, and investigations are still continuing.

Nevertheless, the controversy potentially opens a window of opportunity for InflaRx, whose drug addresses the same target and indication but through a different biochemical mechanism. Importantly, izicopan appears to exert substantially less influence on CYP3A4, a key liver and intestinal enzyme responsible for metabolising around 40–50% of all marketed medicines. Stronger CYP3A4 interaction or inhibition is widely regarded as a warning signal for elevated drug-related side effects. According to recent liver metabolism studies, izicopan has so far shown no such signals.

Broader renal strategy strengthens investor appeal

Beyond AAV, InflaRx is pursuing a broader strategy across complement-mediated kidney diseases. The company plans to generate rapid proof-of-concept data in open-label studies covering additional indications including atypical haemolytic uraemic syndrome (aHUS), IgA nephropathy (IgAN) and C3 glomerulopathy (C3G).

For all three diseases, the C5a/C5aR axis is considered biologically relevant, potentially giving izicopan differentiation opportunities within a growing renal inflammation market. Initial clinical data are expected next year, while a pharmacokinetic bridging study in China is also planned.

Alongside its clinical expansion, InflaRx is reinforcing its balance sheet. The company announced the placement of 75 million shares at US$2.00 per share, generating gross proceeds of US$150m. The funds are intended to support pipeline development and broader corporate activities. The financing attracted both existing and new institutional investors, including several specialist healthcare funds.

With the new capital, InflaRx believes it is funded through multiple value-generating milestones, including Phase II data in AAV and early efficacy signals in additional renal indications. According to current planning, the financing runway now extends into 2029 and could provide the foundation for positioning izicopan as a broadly applicable therapy in the growing market for complement-mediated diseases.

For InflaRx, the situation resembles an unexpected turnaround. Following years of relative obscurity after the pandemic, investor interest has returned sharply — which gives the company the financing to turn to the kidney and accelerate development.